Latest News
BAUS endorses expansion of Abiraterone access
19 January 2026
The British Association of Urological Surgeons (BAUS) - driven by the Section of Oncology - strongly endorses NHS England’s decision to expand access to abiraterone for men with high-risk, non-metastatic prostate cancer. This vital policy change finally eliminates long-standing regional disparities, aligning England with Scotland and Wales. For the 7,000 additional men diagnosed each year, this represents far more than a policy update; it is...